Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00064766
Other study ID # R01HD043175
Secondary ID NIH 1 R01 HD4317
Status Recruiting
Phase Phase 4
First received July 11, 2003
Last updated June 23, 2005
Start date February 2003
Est. completion date February 2005

Study information

Verified date May 2003
Source Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Irregular or prolonged menstrual bleeding and/or spotting are common side effects in patients using progestin-only hormonal contraception such as levonorgestrel implants (Norplant). Doxycycline, a drug approved by the Food and Drug Administration (FDA) to treat gum disease, may reduce the occurrence of uterine bleeding and spotting in women who use Norplant. This study will evaluate the effects of doxycycline on uterine bleeding/spotting in women using Norplant.


Description:

A high percentage of women using progestin-only contraception experience breakthrough bleeding (BTB) and spotting that causes impaired lifestyle and results in decreased compliance with this contraceptive method. There is a need for an effective, low-cost, easily adapted treatment to reduce the bleeding and spotting in progestin-only contraceptives. The molecular environment of the endometrium of women with BTB and spotting contains abnormally high levels of pro-inflammatory cytokines (TNF-alpha and IL-1 beta) and abnormally high levels of proteases (matrix metalloproteinases [MMPs] and neutrophil elastase), which prevent normal tissue repair. Doxycycline (DOX) is an inexpensive, FDA approved antibiotic that inhibits MMPs and reduces nitric oxide synthesis. This study will evaluate DOX treatment of progestin-only contraceptive induced BTB and spotting, characterize the endometrial molecular biologic changes that occur in DOX treated patients, and determine the effect of Norplant on sexual functioning and testosterone levels.

All participants in this study will receive Norplant. Participants will then be randomized to receive either DOX (20 mg twice a day) or placebo for 6 months. Participants will have 9 study visits during the 24 weeks of the study. Study visits will include a medical history, physical exam, and blood and urine tests. Participants will also have three periodontal evaluations and three endometrial biopsies. At the end of the study, participants may choose to have the Norplant implant removed if they wish to discontinue Norplant use; otherwise the implant may remain in for up to 5 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date February 2005
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria

- Regular menstrual periods for the last 2 cycles

- Currently not using hormonal contraceptives, including oral contraceptives, patch, ring, or Norplant in 2 months prior to study entry, or Depo-Provera in 12 months prior to study entry

- Currently not using tetracycline-class antibiotics

- Normal Pap smear

Exclusion criteria

- Pregnancy or breastfeeding within 2 months of study entry

- Chronic migraine headaches

- Uncontrolled high blood pressure

- Untreated sexually transmitted diseases

- Alcoholism or drug abuse within 12 months of study entry

- Insulin dependent diabetes

- Liver, kidney, or gallbladder disease

- Participation in another clinical trial within 30 days of study entry

- History of cancer

- History of blood clots, strokes, or heart disease

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
doxycycline


Locations

Country Name City State
United States CONRAD Clinical Research Center, Eastern Virginia Medical School Norfolk Virginia

Sponsors (1)

Lead Sponsor Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT02618486 - The Effects of Obesity on Non Surgical Periodontal Therapy N/A
Recruiting NCT01785355 - The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients
Completed NCT01639183 - Power Toothbrush Use in Nursing Homes to Eliminate Mouth and Body Inflammation N/A
Completed NCT02935322 - Interaction Between Chlorhexidine and Fluoride Phase 4
Completed NCT00093236 - Impact of Gum Infection on Heart Disease N/A
Completed NCT03444363 - Periodontal Treatment With Diode Laser in the Patients With Diabetes Melitus N/A
Completed NCT03641989 - Correlation Between Oral Health and Systemic Inflammation (COHESION) N/A
Withdrawn NCT02202304 - The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient Phase 4
Recruiting NCT01568697 - Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Completed NCT04873505 - Functional Validation of Lactobacillus Containing Oral Tablet N/A
Completed NCT01521260 - Implant Surface Decontamination in Peri-implantitis Treatment N/A
Recruiting NCT00553007 - The Relation Between Periodontal Disease and Metabolic Syndrome N/A
Completed NCT01399034 - Epigenetics, DNA Methylation Patterns and Periodontal Disease N/A
Recruiting NCT00162838 - Effects of Periodontal Pathogens, Porphyromonas Gingivalis and Tannerella Forsythensis, on Cytokine Production From Human Monocyte-Derived Dendritic Cells N/A
Completed NCT00016835 - Treating Periodontal Infection: Effects on Glycemic Phase 2
Completed NCT03540498 - Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum N/A
Completed NCT03775967 - Estimation of Sialic Acid and IL10 Levels in Stage 1 and 2 Periodontitis Patients
Completed NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT02894463 - Study Aimed at Detecting Potential Abuse of Nitrous Oxide in Children During Dental Care N/A
Completed NCT02289066 - Impact of Periodontal Disease on Outcomes in Diabetes N/A